Determination of Serum Vascular Endothelial Growth Factor Levels in Attention Deficit Hyperactivity Disorder: A Case Control Study
10.9758/cpn.2019.17.4.517
- Author:
Yasemin Taş TORUN
1
;
Esra GÜNEY
;
Arzu ARAL
;
Dicle BÜYÜKTAŞKIN
;
Hüseyin TUNCA
;
Yasemen Işik TANER
;
Elvan İŞERI
Author Information
1. Child and Adolescent Psychiatry Department, Gulhane Education and Training Hospital, Ankara, Turkey. ysmn.ts@gmail.com
- Publication Type:Original Article
- Keywords:
Attention deficit hyperactivity disorder;
Vascular endothelial growth factor;
Children
- MeSH:
Attention Deficit Disorder with Hyperactivity;
Case-Control Studies;
Child;
Enzyme-Linked Immunosorbent Assay;
Healthy Volunteers;
Humans;
Neurodevelopmental Disorders;
Neurons;
Vascular Endothelial Growth Factor A
- From:Clinical Psychopharmacology and Neuroscience
2019;17(4):517-522
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The effect of vascular endothelial growth factor (VEGF) on neuronal development is known, but its relationship with attention deficit hyperactivity disorder (ADHD), a neurodevelopmental disorder, has not yet been fully elucidated. To our knowledge, this is the first human study investigating serum VEGF levels in ADHD patients. In this study, it has been aimed to compare serum VEGF levels between a healthy control group and in ADHD patients to help determine the association between serum VEGF levels and ADHD. METHODS: This study sample included forty-four patients diagnosed with ADHD and 43 healthy volunteer controls between 7 to 14 years old. Blood samples were taken from patients and the healthy control group to assess their serum VEGF levels. VEGF levels were calculated by subjecting the optical densities of the samples to concentrations of known standards as provided in the ELISA kit and then performing a regression correlation analysis. RESULTS: The mean VEGF level of the children was 333.6 ± 209.8 in the ADHD group and 341.3 ± 201.8 in the control group. There were no statistically significant differences in serum VEGF levels between the ADHD and control groups (U = 926.000, z = −0.170, p = 0.865). CONCLUSION: There was no significant difference in serum VEGF levels for untreated ADHD cases and a healthy control group. This is the first human study investigating serum VEGF levels in ADHD patients, so there is a need to replicate these findings.
